23andMe logo

Postdoctoral Fellow, Functional Genomics (Organoid Biology) - 23andMe

View Company Profile
Job Title
Postdoctoral Fellow, Functional Genomics (Organoid Biology)
Job Location
South San Francisco, California
Job Description

Who We Are

23andMe, the leading consumer genetics and research company, has accumulated a wealth of genotypic and phenotypic information from participants committed to improving human health through advances in genomics. Our Therapeutics team in South San Francisco leverages this data to discover and develop new treatments that can offer significant benefits for patients with serious, unmet medical needs.

This dedicated research and drug development group identifies novel targets using 23andMe's genetic database and performs preclinical research to advance programs towards clinical development. We currently have programs across several therapeutic areas, including but not limited to oncology, immunology, and cardiovascular diseases. More information about our Therapeutics team is available at https://therapeutics.23andme.com/.

23andMe has committed to the initiation of a postdoctoral fellowship program that would create opportunities to utilize the 23andMe human genetics platform to conduct cutting-edge science and explore novel biology. Six inaugural fellowships are being offered within the Therapeutics division. The postdoctoral fellow will be expected to focus on innovative, genetics or biological research questions with a goal of presenting their work externally at scientific meetings and publishing in top-ranked peer-reviewed journals. This opportunity will allow postdoctoral fellows to gain exposure to the biotechnology industry to either pursue a career in industry or bring the industry perspective back to an academic career. The fellowships are for a three-year period, with an optional one-year extension. 


Project Summary

The overarching goal of this project is to define the molecular etiology of inflammatory bowel disease. The aim is to set up an in vitro organoid system to study effects of genetic and environmental perturbations as a source of disease pathology. Additionally, the candidate will employ bulk and single cell sequencing to further decipher disease mechanisms in human and mouse tissue.


What You’ll Do

  • Contribute to the establishment of an in vitro model system and various functional assays (including NGS-based) in disease areas of interest (inflammatory bowel disease) to the Therapeutics team at 23andMe
  • Design and lead MOA studies in the inflammatory bowel disease pathology
  • Communicate and collaborate effectively with colleagues to drive progression of the project
  • Maintain compliance with all company policies and procedures


What You’ll Bring

  • PhD in biomedical/biological sciences including but not limited to cancer biology, stem cell biology, molecular biology and/or genetics with 0-2 years of postdoc experience
  • Experience in establishing organoid culture system using mammalian tissue/cells
  • Experience with gene editing/genome perturbation using molecular tools
  • Experience with next generation sequencing data generation and analysis including library preparation and QC
  • Experience in RNA-seq, ATAC-seq, single cell RNA-seq and/or in genome-wide perturbation preferred
  • Basic scripting in R and/or Python preferred
  • Proven ability to work on a cross-functional team and successfully lead a project to decision points
  • Excellent organizational, verbal and written communication skills with the ability to work independently and proactively within a team environment


Strongly Preferred

  • Experience in handling mammalian tissue and working with mouse model 
  • Excellent knowledge of organoid culture including experience with establishing organoids from human and mouse primary tissue
  • Successful record of high-quality publications and/or patent applications



Dr. Abhishek Sohni’s Bio 

Dr. Sohni joined 23andMe in early 2021 as a Scientist in the Functional Genomics group within 23andMe’s Therapeutics division. He obtained his PhD and initial postdoctoral training from KU Leuven (University of Leuven) in Belgium where he used stem cells as a model to study early embryonic and tissue development, he employed genomic approaches to identify non-canonical role of TET1 in early embryo development. As a project scientist at University of California, San Diego, Dr. Sohni used single cell sequencing to surface a rare population of adult stem cells. He is a stem cell and molecular biologist by training with a strong background in next generation sequencing technologies. Dr. Sohni was attracted to 23andMe’s enormous genetic database and his interest in applying NGS based approaches to unravel disease pathology. His primary focus at 23andMe has been applying single cell and genetic editing based approaches to leverage the genetic information and identify potential novel target molecules for drug discovery. 23andMe’s platform empowers him to gain unique insights and understand the genetic bases of human disease and to deliver effective therapeutics.

Dr. Pranidhi Sood’s Bio 

Dr. Sood joined 23andMe at the end of 2021 as a Scientist in the Computational Biology team within the Therapeutics division. She earned her Ph.D. from New York University in Computational Biology where she integrated image analysis and modeling approaches to study how stochastic gene expression shapes the development of multicellular organisms. Before joining 23andMe, she developed genomic tools to uncover the molecular underpinnings of aging, cancer resistance and regenerative biology in non-model organisms, first as a postdoc at UCSF and then as part of the computing team at Calico Labs. At 23andMe, she is applying these genomics approaches to integrate various ‘omics-scale datasets to understand the biological and disease implications of genetic variants identified through 23andMe’s rich genetic database.


About 23andMe

23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80 percent of its customers electing to participate. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. More information is available at www.23andMe.com.

At 23andMe, we value a diverse, inclusive workforce and we provide equal employment opportunity for all applicants and employees. All qualified applicants for employment will be considered without regard to an individual’s race, color, sex, gender identity, gender expression, religion, age, national origin or ancestry, citizenship, physical or mental disability, medical condition, family care status, marital status, domestic partner status, sexual orientation, genetic information, military or veteran status, or any other basis protected by federal, state or local laws.  If you are unable to submit your application because of incompatible assistive technology or a disability, please contact us at accommodations-ext@23andme.com. 23andMe will reasonably accommodate qualified individuals with disabilities to the extent required by applicable law.

Please note: 23andMe does not accept agency resumes and we are not responsible for any fees related to unsolicited resumes. Thank you.

23andMe Headquarters Location

Mountain View, CA

23andMe Company Size

Between 500 - 1,000 employees

23andMe Founded Year


23andMe Funding Rounds

  • Post Ipo Equity

    $250,000,000 USD

  • Series F

    $82,500,000 USD

  • Corporate Round

    $300,000,000 USD

  • Series F

    $250,000,000 USD

  • Grant

    $1,700,000 USD

  • Series E

    $115,000,000 USD

  • Grant

    $1,400,000 USD

  • Series D

    $50,000,000 USD

  • Series C

    $9,000,000 USD

  • Series C

    $22,220,289 USD

  • Series B

    $14,200,000 USD

  • Series B

    $13,600,000 USD

  • Series A

    $8,953,320 USD